Jpmorgan Chase & CO Anavex Life Sciences Corp. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 42,565 shares of AVXL stock, worth $387,767. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,565
Previous 41,374
2.88%
Holding current value
$387,767
Previous $174,000
38.51%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding AVXL
# of Institutions
154Shares Held
27.3MCall Options Held
515KPut Options Held
838K-
Black Rock Inc. New York, NY6.39MShares$58.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.74MShares$43.2 Million0.0% of portfolio
-
State Street Corp Boston, MA3.07MShares$27.9 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.88MShares$17.2 Million0.0% of portfolio
-
Nwam LLC Mercer Island, WA910KShares$8.29 Million0.32% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $710M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...